(-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice

Junko Mimoto, Katsuyuki Kiura, Keisuke Matsuo, Tadashi Yoshino, Ichiro Takata, Hiroshi Ueoka, Mikio Kataoka, Mine Harada

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2% and 2-10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P <0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3% (cisplatin treatment) to 10.8-11.6% (cisplatin plus EGCG treatment) (P <0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.

Original languageEnglish
Pages (from-to)915-919
Number of pages5
JournalCarcinogenesis
Volume21
Issue number5
Publication statusPublished - 2000

Fingerprint

Cisplatin
Carcinogenesis
Lung
Therapeutics
Neoplasms
Weight Loss
Lung Neoplasms
epigallocatechin gallate
Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Carcinogens
Control Groups
Water
Incidence

ASJC Scopus subject areas

  • Cancer Research

Cite this

Mimoto, J., Kiura, K., Matsuo, K., Yoshino, T., Takata, I., Ueoka, H., ... Harada, M. (2000). (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. Carcinogenesis, 21(5), 915-919.

(-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. / Mimoto, Junko; Kiura, Katsuyuki; Matsuo, Keisuke; Yoshino, Tadashi; Takata, Ichiro; Ueoka, Hiroshi; Kataoka, Mikio; Harada, Mine.

In: Carcinogenesis, Vol. 21, No. 5, 2000, p. 915-919.

Research output: Contribution to journalArticle

Mimoto, J, Kiura, K, Matsuo, K, Yoshino, T, Takata, I, Ueoka, H, Kataoka, M & Harada, M 2000, '(-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice', Carcinogenesis, vol. 21, no. 5, pp. 915-919.
Mimoto, Junko ; Kiura, Katsuyuki ; Matsuo, Keisuke ; Yoshino, Tadashi ; Takata, Ichiro ; Ueoka, Hiroshi ; Kataoka, Mikio ; Harada, Mine. / (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice. In: Carcinogenesis. 2000 ; Vol. 21, No. 5. pp. 915-919.
@article{82566833cc914dddafdd5b259e7624d3,
title = "(-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice",
abstract = "Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2{\%} and 2-10{\%} per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3{\%} (5/19) in group 1, 30{\%} (6/20) in group 2, 100{\%} (19/19) in group 3 and 94.4{\%} (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P <0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3{\%} (cisplatin treatment) to 10.8-11.6{\%} (cisplatin plus EGCG treatment) (P <0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.",
author = "Junko Mimoto and Katsuyuki Kiura and Keisuke Matsuo and Tadashi Yoshino and Ichiro Takata and Hiroshi Ueoka and Mikio Kataoka and Mine Harada",
year = "2000",
language = "English",
volume = "21",
pages = "915--919",
journal = "Carcinogenesis",
issn = "0143-3334",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - (-)-Epigallocatechin gallate can prevent cisplatin-induced lung tumorigenesis in A/J mice

AU - Mimoto, Junko

AU - Kiura, Katsuyuki

AU - Matsuo, Keisuke

AU - Yoshino, Tadashi

AU - Takata, Ichiro

AU - Ueoka, Hiroshi

AU - Kataoka, Mikio

AU - Harada, Mine

PY - 2000

Y1 - 2000

N2 - Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2% and 2-10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P <0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3% (cisplatin treatment) to 10.8-11.6% (cisplatin plus EGCG treatment) (P <0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.

AB - Risks of secondary lung cancer in patients with non-small cell lung cancer and small cell lung cancer are estimated to be 1-2% and 2-10% per patient per year, respectively. Cisplatin is widely used in the treatment of lung cancer and is also known as a carcinogen in experimental animals. In this study, the effect of (-)-epigallocatechin gallate (EGCG) on cisplatin-induced lung tumors in A/J mice was investigated. Female A/J mice (4 weeks old) were divided into four groups: group 1, control without treatment; group 2, EGCG treatment (1 mg/ml in tap water); group 3, weekly cisplatin treatment (1.62 mg/kg body wt, i.p.) for 10 weeks; group 4, cisplatin plus EGCG treatment (EGCG was started 2 weeks before cisplatin treatment). Four groups of mice were killed at week 30 after treatment. Tumor incidence was 26.3% (5/19) in group 1, 30% (6/20) in group 2, 100% (19/19) in group 3 and 94.4% (17/18) in group 4. Tumor multiplicity (the number of tumors per mouse, mean ± SD) was 0.4 ± 0.8 in group 1, 0.4 ± 0.8 in group 2, 5.1 ± 2.1 in group 3 and 2.8 ± 2.3 in group 4. Tumor multiplicity was significantly reduced by adding EGCG to cisplatin-treated mice (P <0.01). Furthermore, EGCG significantly reduced cisplatin-induced weight loss from 24.7-26.3% (cisplatin treatment) to 10.8-11.6% (cisplatin plus EGCG treatment) (P <0.01). These findings suggest that EGCG can inhibit cisplatin-induced weight loss and lung tumorigenesis in A/J mice.

UR - http://www.scopus.com/inward/record.url?scp=0034019659&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034019659&partnerID=8YFLogxK

M3 - Article

C2 - 10783312

AN - SCOPUS:0034019659

VL - 21

SP - 915

EP - 919

JO - Carcinogenesis

JF - Carcinogenesis

SN - 0143-3334

IS - 5

ER -